CGRP Antibodies Cut Migraine Days by Half in Over 50% of Real-World Patients | Research

The takeaway

A meta-analysis of 47 real-world studies found that CGRP-targeting antibodies reduced monthly migraine days by about 7.7 days, with 54% of patients achieving at least a 50% reduction.

54% of patients halved their migraines
Over half of real-world patients treated with CGRP antibodies achieved at least a 50% reduction in monthly migraine days across 47 observational studies

What the researchers found

Across 47 observational cohort studies, CGRP monoclonal antibodies showed strong real-world effectiveness for migraine prevention:

- 54% of patients (95% CI 49–59%) achieved at least 50% reduction in monthly migraine days

- Mean monthly migraine reduction: approximately 7.7 days (95% CI 7.0–8.4)

- 57% of patients (95% CI 48–64%) achieved at least 50% reduction in monthly headache days

- Mean monthly headache reduction: approximately 8.8 days (95% CI 7.5–10.1)

Subgroup analyses by specific drug (erenumab, fremanezumab, galcanezumab, eptinezumab) and migraine type showed consistent results.

Why it matters

Clinical trials show drugs work under ideal conditions, but real-world effectiveness often falls short. This meta-analysis demonstrates that CGRP antibodies maintain their effectiveness in everyday clinical practice, where patients often have more complex medical histories and different treatment adherence patterns than trial participants. For the millions of migraine sufferers who haven't responded to traditional preventive treatments, this confirms that CGRP antibodies are a genuinely effective option.

How the study worked

This was a systematic review and meta-analysis of observational cohort studies. Researchers searched electronic databases for real-world studies evaluating CGRP receptor antagonist antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) in adult migraine patients. Primary outcomes were mean reduction in monthly migraine/headache days and the proportion of patients achieving at least 50% reduction. Forty-seven studies met inclusion criteria for qualitative and quantitative analysis.

What this study cannot tell us

Observational studies are inherently subject to selection bias — patients who continue treatment may be the ones responding, inflating effectiveness estimates. There was no placebo comparison group, so the placebo effect and natural regression to the mean cannot be separated from drug effects. Heterogeneity across 47 studies with different methodologies, patient populations, and follow-up durations could affect results. Publication bias may favor positive outcomes. Individual patient data was not available for more granular analysis.

How to read the evidence

This is a systematic review and meta-analysis of observational cohort studies, which provides moderate-to-high quality evidence. While not as rigorous as a meta-analysis of randomized controlled trials, the large number of included studies (47) and consistency with RCT results strengthen the findings. The real-world setting is a strength for generalizability.

When this study was published

Published in 2023, this meta-analysis captures the first several years of real-world CGRP antibody use since these drugs became available around 2018. The evidence base continues to grow as more long-term data accumulates.

The bigger picture

CGRP-targeting therapies represent the first class of migraine preventives specifically designed for migraine rather than repurposed from other conditions (like blood pressure or seizure medications). This meta-analysis of real-world data validates the class and supports broader access. As these drugs become more established and potentially more affordable (with biosimilar competition approaching), this evidence base helps justify their place in migraine treatment guidelines.

Questions still open

Which patient characteristics best predict response to CGRP antibodies, and can this guide treatment selection?
How do CGRP antibodies compare to each other in real-world effectiveness, and should one be preferred as first-line?
What is the long-term (multi-year) effectiveness and safety profile of CGRP antibodies in real-world use?

Common questions

What are CGRP antibodies and how do they prevent migraines?

CGRP (calcitonin gene-related peptide) is a protein released during migraines that causes blood vessel dilation and pain signaling. CGRP antibodies are injectable medications (like Aimovig, Ajovy, and Emgality) that block either CGRP itself or its receptor, preventing this chain reaction. They are taken monthly or quarterly as prevention, not during an active migraine.

How do real-world results compare to clinical trial results for these drugs?

This meta-analysis found that real-world results are consistent with clinical trial findings, which is encouraging. In clinical trials, roughly 50% of patients achieved a 50% or greater reduction in migraine days, and the real-world rate was 54%. This suggests these drugs work just as well in everyday practice as they did in controlled research settings.

Read the original research

Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies.

Clinical drug investigation, 43(9), 669-680

View on PubMed ↗Publisher’s paper ↗

Citation

Ferreira, Vinicius L; Mainka, Felipe F; Wiens, Astrid; Pontarolo, Roberto. (2023). Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies.. Clinical drug investigation, 43(9), 669-680. https://doi.org/10.1007/s40261-023-01301-7